Analysts’ Weekly Ratings Updates for Nurix Therapeutics (NRIX)

Posted by on Apr 14th, 2026

Several analysts have recently updated their ratings and price targets for Nurix Therapeutics (NASDAQ: NRIX):

  • 4/10/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
  • 4/9/2026 – Nurix Therapeutics had its price target lowered by Wells Fargo & Company from $29.00 to $28.00. They now have an “overweight” rating on the stock.
  • 4/8/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $26.00 price target on the stock.
  • 3/24/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.

Insider Buying and Selling at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 4,895 shares of the stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $16.60, for a total transaction of $81,257.00. Following the completion of the sale, the insider directly owned 83,672 shares of the company’s stock, valued at approximately $1,388,955.20. This represents a 5.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Houte Hans Van sold 3,661 shares of the stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $16.60, for a total value of $60,772.60. Following the sale, the chief financial officer directly owned 45,427 shares of the company’s stock, valued at approximately $754,088.20. The trade was a 7.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 6.70% of the company’s stock.

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.

See Also

Receive News & Ratings for Nurix Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.